Novartis
NVS
$121.02
Share price
-2.19%
Change (1 day)
9.52%
Change (1 year)
Categories
Novartis AG is a biotechnology and pharmaceutical company based in Basel, Switzerland. Novartis was formed in 1996 from a merger of the two Basel pharmaceutical and chemical companies Ciba-Geigy AG and Sandoz AG. Novartis is one of the largest pharmaceutical companies in the world with sales of USD 47.4 billion in 2019.
Novartis (NVS) - Total debt
Total debt on the balance sheet as of March 2025 : $31.27 Billion USD
According to Novartis's latest financial reports the company's total debt is $31.27 Billion USD. A company’s total debt is the sum of all current and non-current debts.
Novartis - Total debt on balance sheet (from 2000 to 2025)
Total debt by year
| Year | Total debt | Change |
|---|---|---|
| 2024-12-31 | $31.25 B | 18.64% |
| 2023-12-31 | $26.34 B | -5.59% |
| 2022-12-31 | $27.90 B | -10.04% |
| 2021-12-31 | $31.02 B | -18.04% |
| 2020-12-31 | $37.85 B | 29.87% |
| 2019-12-31 | $29.14 B | -9.17% |
| 2018-12-31 | $32.09 B | 12.89% |
| 2017-12-31 | $28.42 B | 20.01% |
| 2016-12-31 | $23.68 B | 8.15% |
| 2015-12-31 | $21.90 B | 7.57% |
| 2014-12-31 | $20.35 B | 13.64% |
| 2013-12-31 | $17.91 B | -9.18% |
| 2012-12-31 | $19.72 B | -2.49% |
| 2011-12-31 | $20.22 B | -11.83% |
| 2010-12-31 | $22.94 B | 64.96% |
| 2009-12-31 | $13.90 B | 97.7% |
| 2008-12-31 | $7.03 B | 25.78% |
| 2007-12-31 | $5.59 B | -22.49% |
| 2006-12-31 | $7.21 B | -12.1% |
| 2005-12-31 | $8.20 B | 25.18% |
| 2004-12-31 | $6.55 B | 19.87% |
| 2003-12-31 | $5.47 B | 4.43% |
| 2002-12-31 | $5.23 B | 14.74% |
| 2001-12-31 | $4.56 B | 21.57% |
| 2000-12-31 | $3.75 B | -39.72% |
| 1999-12-31 | $6.23 B | -3.82% |
| 1998-12-31 | $6.47 B |
Total debt for similar companies or competitors
| Company | Total debt/th> | differencediff. | Country |
|---|---|---|---|
 Merck MRK | $34.84 B | 11.43% | 🇺🇸 USA |
 Pfizer PFE | $61.29 B | 96.01% | 🇺🇸 USA |
 Johnson & Johnson JNJ | $52.25 B | 67.10% | 🇺🇸 USA |
 Sanofi SNY | $22.77 B | -27.18% | 🇫🇷 France |
 GlaxoSmithKline GSK | $23.81 B | -23.84% | 🇬🇧 UK |
 Teva Pharmaceutical Industries TEVA | $16.93 B | -45.83% | 🇮🇱 Israel |
 Bristol-Myers Squibb BMY | $51.23 B | 63.86% | 🇺🇸 USA |
 Abbott Laboratories ABT | $13.24 B | -57.65% | 🇺🇸 USA |
 AstraZeneca AZN | $31.29 B | 0.08% | 🇬🇧 UK |